Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Core Perspective - Adaptive Biotechnologies and NeoGenomics have entered a multi-year exclusive strategic collaboration to enhance minimal residual disease (MRD) monitoring for patients with specific blood cancers [1][5]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [8]. - NeoGenomics is a premier cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu [9]. Collaboration Details - The partnership will integrate Adaptive's clonoSEQ® test, the first FDA-cleared in vitro diagnostic for MRD detection in lymphoid cancers, with NeoGenomics' COMPASS® and CHART® services [2][3]. - The collaboration aims to provide oncologists with personalized treatment strategies and real-time insights into disease progression for patients with multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma [3][4]. Testing and Monitoring - clonoSEQ testing will be performed by Adaptive's CLIA-certified, CAP-accredited laboratory in Seattle, allowing for ongoing MRD testing throughout the continuum of care [3][4]. - The integration of clonoSEQ with NeoGenomics' services will facilitate longitudinal monitoring of disease burden and enhance the likelihood of patients qualifying for clinical trials [4][5]. Market Position - The collaboration reflects a commitment to providing best-in-class, personalized diagnostic testing for blood cancer patients, strengthening both companies' leadership positions in hematology testing [5].